JP2022549169A5 - - Google Patents
Info
- Publication number
- JP2022549169A5 JP2022549169A5 JP2022517438A JP2022517438A JP2022549169A5 JP 2022549169 A5 JP2022549169 A5 JP 2022549169A5 JP 2022517438 A JP2022517438 A JP 2022517438A JP 2022517438 A JP2022517438 A JP 2022517438A JP 2022549169 A5 JP2022549169 A5 JP 2022549169A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- pharmaceutically acceptable
- acceptable salt
- compound according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025036781A JP2025094953A (ja) | 2019-09-18 | 2025-03-07 | がん治療のためのビアミノキノリンとナノ製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962902156P | 2019-09-18 | 2019-09-18 | |
| US62/902,156 | 2019-09-18 | ||
| PCT/US2020/051430 WO2021055705A1 (en) | 2019-09-18 | 2020-09-18 | Biaminoquinolines and nanoformulations for cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025036781A Division JP2025094953A (ja) | 2019-09-18 | 2025-03-07 | がん治療のためのビアミノキノリンとナノ製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022549169A JP2022549169A (ja) | 2022-11-24 |
| JP2022549169A5 true JP2022549169A5 (cg-RX-API-DMAC10.html) | 2023-09-25 |
| JP7652434B2 JP7652434B2 (ja) | 2025-03-27 |
Family
ID=74884705
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517438A Active JP7652434B2 (ja) | 2019-09-18 | 2020-09-18 | がん治療のためのビアミノキノリンとナノ製剤 |
| JP2025036781A Pending JP2025094953A (ja) | 2019-09-18 | 2025-03-07 | がん治療のためのビアミノキノリンとナノ製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025036781A Pending JP2025094953A (ja) | 2019-09-18 | 2025-03-07 | がん治療のためのビアミノキノリンとナノ製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230348419A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4031543A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7652434B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN115023418B (cg-RX-API-DMAC10.html) |
| CA (1) | CA3154678A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021055705A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020023136A2 (pt) | 2018-05-14 | 2021-02-09 | Nuvation Bio Inc. | compostos de alvo de receptor de hormônio nuclear anticâncer |
| CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
| JP7652434B2 (ja) * | 2019-09-18 | 2025-03-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がん治療のためのビアミノキノリンとナノ製剤 |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4313991A1 (en) | 2021-03-23 | 2024-02-07 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2022235585A1 (en) | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN114948938B (zh) * | 2022-02-22 | 2023-08-11 | 江苏省中医院 | 白术内酯i在制备预防和/或治疗宫颈癌的药物中的用途 |
| CN114948901B (zh) * | 2022-05-06 | 2023-04-21 | 郑州大学第一附属医院 | 一种协同治疗乳腺癌的依西美坦纳米粒、制剂及其制备方法 |
| CN116059172B (zh) * | 2023-02-01 | 2025-05-13 | 中山大学附属第八医院（深圳福田） | 一种纳米递药系统及其制备方法与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2521619A1 (en) * | 2003-04-11 | 2004-10-28 | Taigen Biotechnology | Aminoquinoline compounds |
| EP2547367A4 (en) * | 2010-03-16 | 2016-02-24 | Ge Healthcare Bio Sciences Ab | SYSTEM FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS |
| US20140050696A1 (en) | 2011-04-29 | 2014-02-20 | Ravi K. Amaravadi | Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use |
| WO2015068142A2 (en) * | 2013-11-11 | 2015-05-14 | Cellworks Group, Inc. | Compositions, process of preparation of said compositions, uses and method of management of myeloproliferative disorder |
| EP3177595B1 (en) * | 2014-08-08 | 2021-02-24 | The Trustees Of The University Of Pennsylvania | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy |
| US10774047B2 (en) * | 2015-04-17 | 2020-09-15 | The Trustees Of The University Of Pennsylvania | Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy |
| WO2016196393A2 (en) * | 2015-05-29 | 2016-12-08 | Presage Biosciences, Inc. | Autophagy-inhibiting compounds and uses thereof |
| US20180280372A1 (en) * | 2016-11-22 | 2018-10-04 | Washington University | Compositions and methods for inhibiting autophagy and contraception |
| JP7652434B2 (ja) * | 2019-09-18 | 2025-03-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がん治療のためのビアミノキノリンとナノ製剤 |
-
2020
- 2020-09-18 JP JP2022517438A patent/JP7652434B2/ja active Active
- 2020-09-18 CN CN202080080553.6A patent/CN115023418B/zh active Active
- 2020-09-18 CA CA3154678A patent/CA3154678A1/en active Pending
- 2020-09-18 EP EP20865741.1A patent/EP4031543A4/en active Pending
- 2020-09-18 WO PCT/US2020/051430 patent/WO2021055705A1/en not_active Ceased
- 2020-09-18 CN CN202411558409.5A patent/CN119591543A/zh active Pending
- 2020-09-18 US US17/761,162 patent/US20230348419A1/en active Pending
-
2025
- 2025-03-07 JP JP2025036781A patent/JP2025094953A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008076278A4 (en) | Methods of cancer treatment with igf1r inhibitors | |
| JP2011515478A5 (cg-RX-API-DMAC10.html) | ||
| IL319363A (en) | Cervalon ligands and bifunctional compounds containing them | |
| ES2966336T3 (es) | Formulaciones de inhibidores de cinasa amorfos y métodos de uso de las mismas | |
| JP2011519868A5 (cg-RX-API-DMAC10.html) | ||
| JP2012247438A5 (cg-RX-API-DMAC10.html) | ||
| JP2016519091A5 (cg-RX-API-DMAC10.html) | ||
| JP2019503674A5 (cg-RX-API-DMAC10.html) | ||
| US11001558B2 (en) | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | |
| RU2010120674A (ru) | Полностью человеческие анти-vegf-антитела и способы их применения | |
| JP2017538673A5 (cg-RX-API-DMAC10.html) | ||
| WO2019199621A4 (en) | Bi-functional molecules to degrade circulating proteins | |
| RU2017145267A (ru) | Модуляторы протеолиза на основе имидов и связанные с ними способы применения | |
| JP2014516964A5 (cg-RX-API-DMAC10.html) | ||
| RU2014133019A (ru) | Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы | |
| JP2017513862A5 (cg-RX-API-DMAC10.html) | ||
| RU2018123481A (ru) | Анти-lag3 антитела и антигенсвязывающие фрагменты | |
| JP2014516964A (ja) | 治療用抗ｉｇｆ１ｒ合剤 | |
| IL323835A (en) | Bifunctional small molecules to target the selective degradation of circulating proteins | |
| JP2025509730A5 (cg-RX-API-DMAC10.html) | ||
| EP3826675A1 (en) | Nanoparticle compositions | |
| KR102846292B1 (ko) | Etbr 활성화와 관련된 암을 치료하기 위한 중수소화 화합물, 조성물, 및 방법 | |
| US10512651B2 (en) | Inhibition of MK2 in the treatment of cancer | |
| JP2025509736A5 (cg-RX-API-DMAC10.html) | ||
| US20210275518A1 (en) | Methods of using rebastinib in the treatment of disorders |